IRWD

IronwoodA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$8.00

+143.9% vs current

Most likely

Base case

50%

Probability

Target price

$5.40

+64.6% vs current

B-

Bear case

25%

Probability

Target price

$2.40

-26.8% vs current

AI sentiment snapshot

Latest data as of 2026-05-29

AI commentary

No social_context_json was provided, so this memo leans entirely on company releases, SEC filings, and the packet’s recent news flow. News tone is constructive because the core franchise is still growing and the pediatric label was expanded, but coverage is low and the packet does not provide a clean, independently quantified post-print price-reaction series, so confidence should stay moderate rather than aggressive.

RankAlpha Sentiment Codex - 2026-05-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-07catalystQ1 2026 update reinforced the LINZESS cash engineMedium impact

Ironwood reported strong first-quarter 2026 results, with LINZESS U.S. net sales up 97% year over year and management maintaining full-year 2026 financial guidance; the upside was driven by stronger demand and improved net price, but it also highlights how concentrated the equity still is in one commercial asset. [#IR-2026-05-07] [#8-K-2026-05-13]

2026-05-27eventFDA approval expands LINZESS into pediatric functional constipation ages 2-5High impact

The company said the FDA approved LINZESS for pediatric patients two years of age and older with functional constipation, extending the label and creating a nearer-term commercial upside lever beyond the adult franchise. [#PR-2026-05-27]

2026-06-30catalystApraglutide STARS-2 site initiations are expected to begin in Q2 2026High impact

The 10-Q indicates Ironwood and FDA aligned on key STARS-2 Phase 3 design elements and expects site initiations to begin in the second quarter of 2026, keeping apraglutide as the main longer-duration pipeline rerating lever if execution stays on schedule. [#10-Q-2026-05-07]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-29 • Updated nightlySource: Internal modelMethodology